Home Cart Sign in  
Chemical Structure| 846557-71-9 Chemical Structure| 846557-71-9

Structure of ML385
CAS No.: 846557-71-9

Chemical Structure| 846557-71-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ML385 is an Nrf2 inhibitor that suppresses Nrf2 transcriptional activity with an IC50 value of 1.9 μM. ML385 has antioxidant and antitumor effects and is used in research on cancer and oxidative stress-related diseases.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Huang, Mingcong ; Chang, Jing ; Liu, Yu ; Yin, Jiming ; Zeng, Xiangjun ;

Abstract: Renal hemodynamics damage, an important driving mechanism of diabetic nephropathy (DN), is related to many abnormal endothelial released molecules, such as endothelial nitrogen monoxide synthase (eNOS) and endothelin-1 (ET-1), caused by glomerular endothelial cells dysfunction. Apelin, as the endogenous ligand for APJ, was reported to be associated with endothelial cell dysfunction in diabetes. Therefore, it is hypothesized that apelin/APJ increased renal perfusion in DN through regulating endothelial released molecules. Diabetic models were replicated via injecting STZ intraperitoneally (40 mg/kg/day) for 5 consecutive days. Apelin-13 was infused with micro-osmotic pump at 30 μg/kg/day for 4 weeks. The results showed that apelin increased renal blood flow by increasing phosphorylated eNOS and decreasing ET-1 in diabetic mice, which were cancelled in endothelial-specific APJ knockout mice or whole-body large conductance Ca2+-activated K+ (BKCa) channel knockout rats. Additionally, apelin/APJ activated BKCa channel via increasing expression of BKCa subunits through PI3K/AKT/GSK-3β/Nrf2 pathway but not increasing intracellular Ca2+ concentration under high glucose conditions. In conclusion, this study revealed that apelin/APJ increased renal blood flow in early phase of DN via increasing p-eNOS and decreasing ET-1 in glomerular endothelial cells dependent on PI3K/AKT/GSK-3β/Nrf2 pathway induced expression of BKCa subunits.

Keywords: Diabetic nephropathy ; Renal blood flow ; Endothelial cells ; Apelin ; BKCa channel

Purchased from AmBeed: ; 129203-60-7

Alternative Products

Product Details of ML385

CAS No. :846557-71-9
Formula : C29H25N3O4S
M.W : 511.59
SMILES Code : O=C(NC1=NC(C2=CC=C(N(C(C3=C(C)C=CC=C3)=O)CC4)C4=C2)=C(C)S1)CC5=CC(OCO6)=C6C=C5
MDL No. :MFCD06616124
InChI Key :LINHYWKZVCNAMQ-UHFFFAOYSA-N
Pubchem ID :1383822

Safety of ML385

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
KYSE150 cells 5 μM 48 h ML385 further elevated irradiation-induced ROS, enhancing the irradiation-mediated reduction in cell viability. Cell Death Dis. 2024 Nov 5;15(11):793.
KYSE450 cells 5 μM 48 h Inhibition of NRF2 by ML385 caused a substantial increase in ROS levels and a significant reduction in cell viability. Cell Death Dis. 2024 Nov 5;15(11):793.
N2A cells 5µM Used to investigate the role of the Nrf2 pathway in neuronal itaconate-induced IL-10 expression; results showed that ML385 inhibited 4-OI-induced IL-10 release Front Immunol. 2022 Oct 13;13:1012442.
BV2 cells 2µM Used to investigate the role of the Nrf2 pathway in itaconate-induced IL-10 expression; results showed that ML385 inhibited 4-OI-induced IL-10 release Front Immunol. 2022 Oct 13;13:1012442.
MDA-MB-436 cells 5 μM Inhibited Nrf2 expression, downregulated HBXIP and NQO1 protein expression. NPJ Breast Cancer. 2022 Jan 13;8(1):7.
MG-63 cells 2 µM 2 and 4 h ML385 significantly increased ROS production in MG-63 cells, indicating that Nrf-2 activation is closely related to and negatively regulates ROS generation. Int J Nanomedicine. 2018 May 17;13:2907-2919.
rat nucleus pulposus cells (NPCs) 5 μM To investigate the role of ML385 in inhibiting KGN-mediated antioxidant functions, results showed that ML385 suppressed the expression of antioxidant enzymes in KGN-treated NPCs and led to ECM metabolic imbalance. J Orthop Translat. 2023 Jul 31;42:15-30.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice KYSE150 cell xenograft model 30 mg/kg 5 times per week for 3 weeks ML385 significantly suppressed ΔNp63α-mediated tumor growth, indicating that NRF2 inhibition can counteract ΔNp63α-mediated radioresistance. Cell Death Dis. 2024 Nov 5;15(11):793.
Mice Subarachnoid hemorrhage model Intraperitoneal injection 30 mg/kg Single injection, lasting 30 minutes ML385 blocked the Keap1/Nrf2 signaling pathway, inhibiting the antioxidant effects of EDB and EDA. Front Pharmacol. 2024 May 30;15:1342226
Mice Middle cerebral artery occlusion model Intraperitoneal injection 30 mg/kg Once daily for 7 days To evaluate the effect of ML385 on the Nrf2/HO-1 signaling pathway, ML385 treatment reversed the influence of curcumol on microglial polarization Cell Death Discov. 2024 Jun 24;10(1):300.
BALB/c mice LPS-induced sickness behavior model Intraperitoneal injection 30 mg/kg Single injection, lasting 24 hours To evaluate the effect of ML385 on the protective effects of DMF, results showed that ML385 reversed the protective effects of DMF on LPS-induced sickness behavior. Front Immunol. 2021 Nov 10;12:737065

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.95mL

0.39mL

0.20mL

9.77mL

1.95mL

0.98mL

19.55mL

3.91mL

1.95mL

References

 

Historical Records

Categories